US2022090136A1PendingUtilityA1
Sin nombre virus full-length m segment-based dna vaccines
Est. expiryJan 31, 2031(~4.5 yrs left)· nominal 20-yr term from priority
Inventors:Jay Hooper
A61K 39/12C07K 16/10C12N 15/86C12N 7/00C07K 14/005A61K 2039/53C12N 15/102C12N 2760/12143A61K 2039/70C12N 2760/12122C12N 2760/12121C12N 2760/12171A61K 2039/575C12N 2760/12151C12N 2760/12111C12N 2760/12134
73
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Claims
exact text as granted — not AI-modified1 . A therapeutic composition for ameliorating symptoms after onset of Sin Nombre virus infection comprising antibodies specific for peptides encoded by the nucleic acid having the sequence set forth in SEQ ID NO:3.
Join the waitlist — get patent alerts
Track US2022090136A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.